Catalyst
Slingshot members are tracking this event:
FORWARD-5 trial on ALKS-5461 in treating major depressive disorder yields positive results; Alkermes to request pre-NDA meeting in second quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 18, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-EventDetails&EventId=5251798
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Alks-5461, Major Depressive Disorder, Phase 3 Study, Forward-5
